What is the 13F Pro Quality Score for OCUL?

13F Pro ranks OCULAR THERAPEUTIX, INC (OCUL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View OCUL's current score at https://13fpro.ai/company/OCUL (free sign-up required for the full ranking).

Which hedge funds own the most OCUL stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of OCUL include FMR, Deep Track Capital,, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/OCUL as soon as new 13F filings post.

Where does 13F Pro source OCUL data?

All OCULAR THERAPEUTIX, INC fundamentals and ownership data come directly from SEC EDGAR. OCULAR THERAPEUTIX, INC files with the SEC under CIK 1393434. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is OCUL in?

OCULAR THERAPEUTIX, INC (OCUL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is OCUL research updated on 13F Pro?

OCUL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

OCULAR THERAPEUTIX, INC(OCUL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1393434 OCUL stock profile & AI dashboard →

13F Pro Quality Score

8.4/100

Rank #2,930 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

9.6/100

Profitability

3.0/100

Balance Sheet

3.1/100

Earnings Quality

23.3/100

Free Cash Flow

2.8/100

Institutional Flow

24.1/100

Revenue Scale

9.2/100

Dilution Risk

3.5/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why OCUL Scores 8/100

exact factor attribution · 2026-09-11

OCUL's composite is held back by revenue growth and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

-1.3 pts

24th pct

Earnings growth

-2.3 pts

4th pct

Shareholder dilution

-2.3 pts

4th pct

Earnings quality

-2.7 pts

23th pct

Capital efficiency

-4.7 pts

3th pct

Scale

-6.1 pts

9th pct

Profitability

-7.0 pts

3th pct

Free cash flow

-7.1 pts

3th pct

Revenue growth

-8.1 pts

10th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

OCUL Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for OCULAR THERAPEUTIX, INC (OCUL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores OCUL at 8.4/100 on a 32-signal composite quality model, placing it at rank #2,930 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (2.8) and profitability (3.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), OCULAR THERAPEUTIX, INC reports quarterly revenue of $13.5M, net income of $-78.8M, free cash flow of $-70.6M. Top institutional holders of OCUL by reported 13-F value include FMR, Deep Track Capital, BlackRock, based on the most recent SEC filings. OCUL trades on the Nasdaq exchange and files with the SEC under CIK 1393434. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OCUL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for OCULAR THERAPEUTIX, INC directly from SEC EDGAR. OCULAR THERAPEUTIX, INC's 13F Pro composite quality score has ranged between 8 and 36 since 2021, currently 8.4 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about OCULAR THERAPEUTIX, INC

Quirks, history, and lore behind OCUL — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. specialty biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in Massachusetts.
2
The Numbers
Annual revenue in the low tens of millions of dollars, with most of it driven by a single commercial product — the classic biotech bet-everything-on-one-drug model.
3
The History
Founded in the early 2000s, the company built its entire platform around a proprietary hydrogel drug-delivery technology designed to release medicine slowly and precisely at a target site.
4
The Secret
The secret weapon is a biodegradable, water-swelling gel that doubles as both the drug depot and the implant — no removal procedure required, because it dissolves on its own.
5
The Lore
Its lead approved product, Dextenza, is a tiny sustained-release insert placed inside the lower eyelid after eye surgery to deliver steroids without daily drops — patients love not having to remember anything.
6
The Giveaway
The name is basically a spoiler: it's a company laser-focused on ocular drug delivery, with a pipeline of eye-drop-killing implants for conditions from post-op inflammation to dry eye disease.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$13.5M

Net Income

Q2 2026

$-78.8M

Free Cash Flow

Q2 2026

$-70.6M

ROIC

Q2 2026

-63.2%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-18.5% YoY

$52.0MFY 2025

FY22 $51.5MFY23 $58.4MFY24 $63.7MFY25 $52.0M

Net Income

-37.4% YoY

$-265.9MFY 2025

FY22 $-71.0MFY23 $-80.7MFY24 $-193.5MFY25 $-265.9M

Operating Income

-57.2% YoY

$-270.0MFY 2025

FY22 $-78.7MFY23 $-82.4MFY24 $-171.8MFY25 $-270.0M

EPS (Diluted)

-16.4% YoY

$-1.42FY 2025

FY22 $-0.97FY23 $-1.02FY24 $-1.22FY25 $-1.42

Total Assets

+76.5% YoY

$808.1MFY 2025

FY22 $149.3MFY23 $252.1MFY24 $457.9MFY25 $808.1M

Op. Cash Flow

-52.1% YoY

$-204.9MFY 2025

FY22 $-59.6MFY23 $-70.2MFY24 $-134.7MFY25 $-204.9M

Free Cash Flow

-59.5% YoY

$-216.9MFY 2025

FY22 $-63.3MFY23 $-76.3MFY24 $-136.0MFY25 $-216.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$52.0M -18.5%	$63.7M +9.0%	$58.4M +13.5%	$51.5M +18.3%	$43.5M +150.1%	$17.4M
Net Income	$-265.9M -37.4%	$-193.5M -139.7%	$-80.7M -13.7%	$-71.0M -984.1%	$-6.6M +95.8%	$-155.6M
Operating Income	$-270.0M -57.2%	$-171.8M -108.5%	$-82.4M -4.7%	$-78.7M -0.8%	$-78.0M -24.2%	$-62.8M
EPS (Diluted)	$-1.42 -16.4%	$-1.22 -19.6%	$-1.02 -5.2%	$-0.97 +1.0%	$-0.98 +61.7%	$-2.56
Total Assets	$808.1M +76.5%	$457.9M +81.7%	$252.1M +68.8%	$149.3M -27.1%	$204.9M -21.8%	$261.9M
Operating Cash Flow	$-204.9M -52.1%	$-134.7M -91.8%	$-70.2M -17.8%	$-59.6M +9.1%	$-65.5M -22.4%	$-53.6M
Free Cash Flow	$-216.9M -59.5%	$-136.0M -78.1%	$-76.3M -20.5%	$-63.3M +5.1%	$-66.7M -22.7%	$-54.4M

Get alerted when OCUL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for OCULAR THERAPEUTIX, INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of OCUL

FMR LLC
$322.5M32,844,043 sh
Deep Track Capital, LP
$193.3M19,686,282 sh
BlackRock, Inc.
$190.3M19,376,555 sh
Avoro Capital Advisors LLC
$123.1M12,540,000 sh
SUMMER ROAD LLC
$119.9M12,208,296 sh
VR Adviser, LLC
$101.6M10,346,926 sh
VANGUARD CAPITAL MANAGEMENT LLC
$86.7M8,832,595 sh
PRICE T ROWE ASSOCIATES INC /MD/
$74.9M7,623,533 sh
Logos Global Management LP
$52.0M5,300,000 sh
STATE STREET CORP
$51.4M5,233,282 sh

Fund	Value	Shares
FMR LLC	$322.5M	32,844,043
Deep Track Capital, LP	$193.3M	19,686,282
BlackRock, Inc.	$190.3M	19,376,555
Avoro Capital Advisors LLC	$123.1M	12,540,000
SUMMER ROAD LLC	$119.9M	12,208,296
VR Adviser, LLC	$101.6M	10,346,926
VANGUARD CAPITAL MANAGEMENT LLC	$86.7M	8,832,595
PRICE T ROWE ASSOCIATES INC /MD/	$74.9M	7,623,533
Logos Global Management LP	$52.0M	5,300,000
STATE STREET CORP	$51.4M	5,233,282

Companies Similar to OCUL

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

DNTH

Dianthus Therapeutics, Inc. /DE/

AI score

Very similar · 17 shared holders

VR Adviser, LLC Logos Global Management LP Octagon Capital Advisors LP

AVTX

Avalo Therapeutics, Inc.

AI score

Very similar · 8 shared holders

Deep Track Capital, LP Avoro Capital Advisors LLC Logos Global Management LP

TSHA

Taysha Gene Therapies, Inc.

AI score

Very similar · 8 shared holders

Avoro Capital Advisors LLC Octagon Capital Advisors LP ACUTA CAPITAL PARTNERS, LLC

QURE

uniQure N.V.

AI score

Similar quality profile · 12 shared holders

Avoro Capital Advisors LLC Boxer Capital Management, LLC ORBIMED ADVISORS LLC

XNCR

Xencor Inc

AI score

Similar quality profile · 10 shared holders

TCG Crossover Management, LLC Deep Track Capital, LP Erste Asset Management GmbH

NRIX

Nurix Therapeutics, Inc.

AI score

Similar quality profile · 11 shared holders

Deep Track Capital, LP Candriam S.C.A.HighVista Strategies LLC

ARCT

Arcturus Therapeutics Holdings Inc.

AI score

Similar quality profile · 7 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC Empire Life Investments Inc.nVerses Capital, LLC

STOK

Stoke Therapeutics, Inc.

AI score

Similar quality profile · 10 shared holders

Candriam S.C.A.Opaleye Management Inc.Rhenman & Partners Asset Management AB

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put OCUL on your watchlist

Track score changes the day OCULAR THERAPEUTIX, INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is OCUL a good stock to buy?

13F Pro's AI-powered analysis of OCULAR THERAPEUTIX, INC (OCUL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OCUL are available on the OCUL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. OCUL is classified as a mid company.

Which hedge funds own OCUL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OCUL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of OCULAR THERAPEUTIX, INC's investment landscape.